We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$194M
Cap. Flow %
-10.46%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.69%
2 Healthcare 6.69%
3 Materials 0.25%
4 Financials 0.16%
5 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
151
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$748K 0.04%
219,712
+208,330
+1,830% +$985K
FWP
152
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$733K 0.04%
4,857
-10,039
-67% -$1.89M
DRNA
153
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$680K 0.04%
200,000
+100,000
+100% +$282K
GENE
154
DELISTED
Genetic Technologies Ltd.
GENE
$678K 0.04%
28,504
-25,013
-47% -$570K
DRWI
155
DELISTED
DragonWave Inc
DRWI
$677K 0.04%
+466,696
New +$800K
RIBT
156
DELISTED
RiceBran Technologies
RIBT
$670K 0.04%
77,956
-9,573
-11% -$85K
CASC
157
DELISTED
Cascadian Therapeutics, Inc.
CASC
$669K 0.04%
+161,670
New +$680K
LRMR icon
158
Larimar Therapeutics
LRMR
$396M
$668K 0.04%
11,943
-13,890
-54% -$690K
PTN
159
Palatin Technologies
PTN
$19.7M
$663K 0.04%
1,621
+283
+21% +$141K
VIRX
160
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$661K 0.04%
+46
New +$6.58K
BLUE
161
PUT
DELISTED
bluebird bio
BLUE
$654K 0.04%
+6
New +$6.12K
DRRX
162
CALL
DELISTED
DURECT Corp
DRRX
$653K 0.04%
622
-71
-10% -$759
PTCT icon
163
PUT
PTC Therapeutics
PTCT
$5.47B
$639K 0.03%
649
+52
+9% +$629
AIM
164
AIM ImmunoTech
AIM
$7.97M
$638K 0.03%
266
-51
-16% -$130K
VIRX
165
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$632K 0.03%
4,405
-1,919
-30% -$274K
ZGNX
166
DELISTED
Zogenix, Inc.
ZGNX
$626K 0.03%
+57,700
New +$585K
TGTX icon
167
CALL
TG Therapeutics
TGTX
$8.17B
$571K 0.03%
+490
New +$3.52K
TGTX icon
168
PUT
TG Therapeutics
TGTX
$8.17B
$569K 0.03%
488
-360
-42% -$2.58K
BPTH
169
DELISTED
Bio-Path Holdings Inc
BPTH
$569K 0.03%
172
+6
+4% +$21.8K
NTRP icon
170
NextTrip
NTRP
$25M
$565K 0.03%
+911
New +$626K
MTFBW
171
DELISTED
Motif Bio plc Warrants to Purchase ADRs
MTFBW
$555K 0.03%
411,372
-14,798
-3% -$20.9K
ONTXW
172
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$544K 0.03%
650,750
-40,322
-6% -$28.9K
FOCL
173
PUT
EDAP TMS S.A.
FOCL
$191M
$540K 0.03%
1,943
+1,602
+470% +$4.83K
PTCT icon
174
PTC Therapeutics
PTCT
$5.47B
$539K 0.03%
+54,736
New +$663K
LXRX icon
175
PUT
Lexicon Pharmaceuticals
LXRX
$859M
$538K 0.03%
375
+254
+210% +$3.77K
5 6
7
8 9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $194M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 81% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.